Failure of ex-US Kevzara phase 3 further dents IL-6 COVID-19 hypothesis 01-Sep-2020 By Nick Taylor Sanofi’s Kevzara fails to beat placebo in COVID-19 phase 3, further diminishing hopes of repurposing anti-IL-6 antibodies.